Rafael Overview
Industry: Real Estate Services
Sector: Real Estate
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), that is in Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey. Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that explo Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Rafael into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $0.2M (-51% YoY). Net loss was -$4.1M (-79% YoY). R&D expense was $4.9M.
What changed
- Revenue -51% YoY to $0.2M.
- Net loss -79% YoY to -$4.1M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Heineken (ENXTAM:HEIA) Backs Rafael Oliveira As Next CEO From October 2026
Headline from Yahoo Finance: Heineken (ENXTAM:HEIA) Backs Rafael Oliveira As Next CEO From October 2026.
Wabtec CEO Rafael Santana sells $693,223 in WAB stock
Headline from Investing.com: Wabtec CEO Rafael Santana sells $693,223 in WAB stock.
This Date in Baseball - Rafael Furcal turns the 12th unassisted triple play in major league history
Headline from AP News: This Date in Baseball - Rafael Furcal turns the 12th unassisted triple play in major league history.
HEINEKEN N.V. GENERAL MEETING APPROVES APPOINTMENT RAFAEL
Headline from GlobeNewswire: HEINEKEN N.V. GENERAL MEETING APPROVES APPOINTMENT RAFAEL.
ATP roundup: Taylor Fritz bests Rafael Jodar for DC Open title
Headline from Reuters: ATP roundup: Taylor Fritz bests Rafael Jodar for DC Open title.
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.